

Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies

Neurol Neuroimmunol Neuroinflamm 2021;8:e1013. doi:10.1212/NXI.0000000000001013

In the article “Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies” by S.-H. Kim et al,¹ Su-Hyun Kim’s contributions listed in the appendix should be “Drafting/revision of the manuscript for content, major role in the acquisition of data, study concept or design, and analysis or interpretation of data.” The publisher regrets the error.

Reference

1. Kim S-H, Jang H, Park NY, et al. Discontinuation of immunosuppressive therapy in patients with neuromyelitis optica spectrum disorder with aquaporin-4 antibodies. *Neurol Neuroimmunol Neuroinflamm* 2021;8:e947. doi: 10.1212/NXI.0000000000000947.